Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-Cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors (HALT) - A Pilot Study

NCT06151730 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06151730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06151730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-Cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors (HALT) - A Pilot Study
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Recruiting
Start date
January 5, 2024
Completion date
June 30, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, hematopoietic and lymphoid system neoplasm, mantle cell lymphoma, marginal zone lymphoma, waldenstrom macroglobulinemia